The nation of Zimbabwe has declined a major American health deal valued at 367 million US dollars (272 million pounds) over five years over the United States' insistence on sensitive information.
This rejection came to light following a official document dated December was disclosed, revealing that Head of State Emmerson Mnangagwa deemed the agreement was "unbalanced".
A government spokesman later stated that the United States was seeking health data for scientific study and profit while was unwilling to share the resulting advantages from future medical innovations.
"We are forced to start the difficult and regrettable process of ending our support in Zimbabwe," said American envoy to Zimbabwe Pamela Tremont publicly.
Her embassy said the US had furnished more than $1.9bn in health funding to Zimbabwe during the past twenty years.
A medical body in Zimbabwe has urged more talks to reach a deal agreeable to all parties so the nation's critical HIV programme can proceed.
Wider Context
This rejection comes after a similar case in Kenya, where a high court suspended a similar deal with the US after legal challenges were raised about the security of citizens' health data.
Since returning to office last year, US President Donald Trump has reduced foreign aid and shut down the US Agency for International Development (USAID).
USAID had overseen assistance for the US government, but Trump argued its spending was "inefficient" and his administration was pursuing direct bilateral agreements to enhance openness and accountability.
Based on statements, Sixteen African countries have so far signed similar health pacts, constituting more than $18.3bn in new funding.
Details of the Rejected Deal
The money for Zimbabwe was intended to gone towards "combating HIV/Aids, tuberculosis, malaria, healthcare for mothers and children, and preparing for epidemics".
"We believe this collaboration might have yielded significant advantages for the people of Zimbabwe, especially the 1.2 million currently on HIV treatment through US-supported programmes," the Ambassador said.
However, government spokesperson Nick Mangwana said the proposed deal was "asymmetrical".
"Zimbabwe was being asked to provide its genetic material and health information indefinitely, with no corresponding assurance of access to any scientific breakthroughs – like vaccines, diagnostics, or treatments – that could be developed from that shared data," Mangwana explained.
"Effectively, our nation would supply the basic resources for medical research without any assurance that the resulting innovations would be available to our people if a future health crisis emerge."
National Interest and Global Health
He also said that the US's withdrawal from the global health body and its push of one-on-one deals were undermining systems previously set up through the international organization.
The spokesperson gave as an example its Pathogen Access and Benefit Sharing framework designed to manage potential global health emergencies.
"This system is designed to ensure that when a country contributes its information, the benefits – including vaccines and treatments – are shared equitably, not monopolised exclusively by those with the funds to develop them."
The government's concerns regarding the US deal "should not be misconstrued as opposition to America," he added.
"We encourage further discussions with our American counterparts on how future co-operation could be structured in a manner that honours the sovereignty and dignity of each country."
Health Experts Reaction
Medical experts said it recognised the government's concerns, but urged that talks need to persist since much of the country's HIV programmes depended on external financing.
"Where technical issues arise, such as those involving information security or agreement terms, these can frequently be resolved through detailed discussion and negotiated safeguards," it said.
The situation highlights the ongoing challenges between receiving much-needed international aid and protecting national sovereignty in an ever more interconnected world.